Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 4 1Phase 3 1Phase 2/3 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 13Bevacizumab 9Saline Solution 8Bupivacaine 8Tobacco Use Cessation Devices 7Specimen Handling 7Nivolumab 7Magnetic Resonance Spectroscopy 7Lenalidomide 7Fluorouracil 7pembrolizumab 6Rituximab 6Prednisone 6Letrozole 6Cisplatin 6Carboplatin 6Sodium Chloride 5Ropivacaine 5Propofol 5Human Papillomavirus Recombinant Vaccine nonavalent 5trametinib 4lenvatinib 4dabrafenib 4cabozantinib 4anlotinib 4Trastuzumab 4Tamoxifen 4Standard of Care 4Paclitaxel 4Immune Checkpoint Inhibitors 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Medrol Veriderm × 1 year × Clear all
NCT07101445 2026-02-10

Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial

Emory University

Phase 4 Recruiting
94 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡